Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
REMODULIN vs VERTAVIS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Treprostinil is a synthetic prostacyclin analog that directly vasodilates pulmonary and systemic arterial beds, inhibits platelet aggregation, and suppresses smooth muscle proliferation.
Vertavis is an inhibitor of acetylcholinesterase, increasing acetylcholine levels at cholinergic synapses.
Pulmonary arterial hypertension (WHO Group I) to improve exercise capacity and reduce symptoms,Off-label: Severe Raynaud's phenomenon, digital ischemia, and salvage therapy for PAH in patients failing other prostacyclins
Treatment of mild to moderate Alzheimer's disease,Off-label: treatment of other dementias, myasthenia gravis
Continuous subcutaneous infusion: Initially 1.25 ng/kg/min; increase by 1.25 ng/kg/min every week for first 4 weeks, then by 2.5 ng/kg/min every week as tolerated. Intravenous infusion: same dosing.
5 mg orally three times daily. May be increased to 10 mg three times daily if tolerated.
Terminal elimination half-life is approximately 4 hours (range 2-7 hours) following continuous subcutaneous infusion; clinical context: requires continuous infusion due to short half-life.
Terminal elimination half-life is 39–58 hours (mean 49 hours), supporting once-daily dosing. Steady state is achieved after 7–10 days.
Hepatic metabolism via CYP2C8 and CYP2C9 (major), with minor contributions from CYP2C19 and CYP2D6; major metabolite is a glucuronide conjugate.
Primarily hydrolyzed by plasma esterases; minor hepatic metabolism via CYP450 enzymes.
Renal: 20-30% as unchanged drug; fecal: 70-80% as metabolites (via biliary elimination).
Approximately 70% of the dose is excreted renally as unchanged drug and 30% via biliary/fecal routes as metabolites.
Approximately 58% bound to human plasma proteins, primarily to albumin.
Approximately 99% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Volume of distribution (Vd) is 1.3 L/kg (range 0.8-2.0 L/kg); clinical meaning: extensive distribution into tissues, exceeding total body water.
Volume of distribution is 0.4–0.6 L/kg (approx 30–50 L in adults), indicating distribution primarily into extracellular fluid.
Subcutaneous: approximately 100% bioavailable compared to intravenous; oral: negligible (not administered orally).
Oral bioavailability is approximately 50% (range 30–70%) with food reducing rate but not extent of absorption.
No dosage adjustment required for renal impairment.
No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (e GFR <30 m L/min/1.73 m²), use is not recommended.
Mild to moderate hepatic impairment (Child-Pugh class A or B): no adjustment. Severe hepatic impairment (Child-Pugh class C): contraindicated.
Not recommended for use in patients with moderate to severe hepatic impairment (Child-Pugh class B or C). No data available.
Not established; safety and efficacy in pediatric patients have not been studied.
Safety and efficacy not established; no recommended dose.
No specific dose adjustment recommended; use with caution due to age-related renal/hepatic decline.
No specific dose adjustment; use with caution due to potential increased sensitivity and comorbidities.
None. However, infusion site reactions (pain, erythema, induration) and risk of catheter-related bloodstream infections are significant concerns.
No FDA black box warning.
Sudden discontinuation may worsen PAH; taper if possible.,Infusion site reactions are common; avoid extravasation.,Risk of bleeding due to antiplatelet effects; use with caution in patients with peptic ulcer disease or on anticoagulants.,Hepatic impairment may increase exposure; dosage adjustment may be needed.,May cause systemic hypotension; monitor blood pressure.
Cardiovascular effects (bradycardia, syncope),Gastrointestinal effects (nausea, vomiting, diarrhea),Seizures,Weight loss
Known hypersensitivity to treprostinil or any excipient,Patients with severe hepatic impairment (Child-Pugh class C) due to lack of safety data
Hypersensitivity to Vertavis or any component,History of severe cholinergic adverse effects
There are no known food interactions with treprostinil. However, patients should maintain a balanced diet as part of overall PAH management. Grapefruit juice has not been reported to interact, but always consult with a healthcare provider.
Avoid grapefruit and grapefruit juice as they may increase ergotamine levels and risk of toxicity. Limit caffeine intake as it can exacerbate headache and interact with ergotamine. Avoid tyramine-rich foods (aged cheese, cured meats, fermented products) if migraines are triggered by tyramine.
Teriprostinil (REMODULIN) is contraindicated in pregnancy due to teratogenic effects in animal studies (increased cardiovascular and skeletal malformations). There are no adequate human data; however, based on animal findings, fetal risk cannot be excluded, particularly in the first trimester. In later trimesters, risks include potential fetal harm from maternal hypotension and hypoxia.
Contraindicated in pregnancy. FDA Pregnancy Category X. In animals, ribociclib (active ingredient) caused embryotoxicity, fetotoxicity, and teratogenicity at maternal exposures below human clinical exposure at 400 mg/day. First trimester: high risk of major congenital malformations; second and third trimesters: risk of fetal growth restriction and fetal death.
It is unknown if teriprostinil is excreted in human milk. M/P ratio not established. Due to potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during treatment and for at least 48 hours after the last dose.
Contraindicated during breastfeeding. No data on presence in human milk; however, animal studies show drug and metabolites are excreted in milk. M/P ratio not known. Due to potential for serious adverse reactions in breastfed infants, advise women not to breastfeed during treatment and for at least 3 weeks after last dose.
Pregnancy is a contraindication; thus no dose adjustments are applicable. However, if used in exceptional circumstances, plasma volume expansion in pregnancy may alter drug distribution, but specific dose recommendations are lacking. Use is not recommended.
No dose adjustments recommended during pregnancy as the drug is contraindicated. If unintentionally exposed, discontinue immediately. Physiologic changes in pregnancy may alter drug pharmacokinetics (e.g., increased volume of distribution, increased hepatic clearance), but no specific dose adjustment has been studied in pregnant women.
REMODULIN (treprostinil) is a prostacyclin analog used for pulmonary arterial hypertension (PAH). Avoid abrupt discontinuation due to risk of rebound pulmonary hypertension. Monitor for infusion site reactions and bleeding risk due to antiplatelet effects. Dose titration should be guided by PAH symptoms and side effects. Use with caution in patients with hepatic impairment.
Vertavis (a combination of phenobarbital, ergotamine, and belladonna alkaloids) is used for migraine and tension-type headaches. Monitor for signs of ergotism (numbness, cold extremities, muscle pain) due to ergotamine; avoid prolonged use. Phenobarbital is a controlled substance (C-IV) with abuse potential; monitor for sedation and dependence. Belladonna alkaloids cause anticholinergic effects (dry mouth, blurred vision, urinary retention). Taper dose to avoid withdrawal; avoid in patients with peripheral vascular disease, coronary artery disease, or glaucoma.
Do not stop taking this medication suddenly; sudden cessation may cause worsening of symptoms.,Report any signs of bleeding (e.g., easy bruising, nosebleeds, blood in urine or stool) to your healthcare provider.,If using subcutaneous infusion, rotate injection sites to prevent site reactions and infection.,Store medication as directed; do not freeze or expose to excessive heat.,Avoid activities that increase bleeding risk, such as contact sports, until you discuss with your doctor.
Take Vertavis at the first sign of headache; do not exceed recommended dose.,Do not use more than 10 days per month to avoid medication-overuse headache and ergotamine toxicity.,Report symptoms of ergotism such as cold fingers or toes, numbness, tingling, or muscle pain immediately.,This medication may cause drowsiness or dizziness; avoid driving or operating machinery until you know how you react.,Avoid alcohol; it can increase sedation and ergotamine side effects.,Do not suddenly stop taking this medication; withdrawal may cause rebound headaches or seizures.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about REMODULIN vs VERTAVIS, answered by our medical review team.
REMODULIN is a Prostacyclin Vasodilator that works by Treprostinil is a synthetic prostacyclin analog that directly vasodilates pulmonary and systemic arterial beds, inhibits platelet aggregation, and suppresses smooth muscle proliferation.. VERTAVIS is a Prostacyclin Vasodilator that works by Vertavis is an inhibitor of acetylcholinesterase, increasing acetylcholine levels at cholinergic synapses.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between REMODULIN and VERTAVIS depend on the specific clinical indication. These are both Prostacyclin Vasodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of REMODULIN is: Continuous subcutaneous infusion: Initially 1.25 ng/kg/min; increase by 1.25 ng/kg/min every week for first 4 weeks, then by 2.5 ng/kg/min every week as tolerated. Intravenous infusion: same dosing.. The standard adult dose of VERTAVIS is: 5 mg orally three times daily. May be increased to 10 mg three times daily if tolerated.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between REMODULIN and VERTAVIS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. REMODULIN is classified as Category C. Teriprostinil (REMODULIN) is contraindicated in pregnancy due to teratogenic effects in animal studies (increased cardiovascular and skeletal malformations). There are no adequate . VERTAVIS is classified as Category C. Contraindicated in pregnancy. FDA Pregnancy Category X. In animals, ribociclib (active ingredient) caused embryotoxicity, fetotoxicity, and teratogenicity at maternal exposures bel. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.